(Q43046741)

English

Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b

scientific article published in March 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

ChEBI release 2020-05-28

Hepatitis C virus

1 reference

based on heuristic

inferred from title

pegylated interferon

1 reference

based on heuristic

inferred from title

author name string

J Vermehren

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

S Susser

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

C M Lange

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

N Forestier

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

U Karey

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

E Hughes

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

R Ralston

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

X Tong

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

S Zeuzem

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

C Sarrazin

10

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

publication date

1 March 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Journal of Viral Hepatitis

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

120-127

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01449.X

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01449.X

21 January 2018

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01449.X

21 January 2018

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01449.X

21 January 2018

Resistance to direct antiviral agents in patients with hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01449.X

21 January 2018

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01449.X

21 January 2018

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01449.X

21 January 2018

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01449.X

21 January 2018

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01449.X

21 January 2018

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01449.X

21 January 2018

Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01449.X

21 January 2018

Characterization of resistance mutations against HCV ketoamide protease inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01449.X

21 January 2018

Identification of HCV protease inhibitor resistance mutations by selection pressure-based method

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01449.X

21 January 2018

Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01449.X

21 January 2018

Natural presence of substitution R155K within hepatitis C virus NS3 protease from a treatment-naïve chronically infected patient

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01449.X

21 January 2018

Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01449.X

21 January 2018

Temporal Dynamics of a Predominant Protease Inhibitor–Resistance Mutation in a Treatment-Naive, Hepatitis C Virus–Infected Individual

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01449.X

21 January 2018

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01449.X

21 January 2018

Use of HIV resistance testing after prolonged treatment interruption.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01449.X

21 January 2018

Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01449.X

21 January 2018

Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01449.X

21 January 2018

Immunology of hepatitis B virus and hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01449.X

21 January 2018

Structural biology of HIV.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01449.X

21 January 2018

Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01449.X

21 January 2018

Identifiers

10.1111/J.1365-2893.2011.01449.X

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43046741&oldid=2224330181"